European Commission approves Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) to treat HIV.-Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the first TAF-based regimen to receive marketing authorization in the European Union (EU).
Genvoya is indicated in the EU for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with HIV-1 without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.
Comment: Gilead claims that Genvoya was as good as Stribild ( (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)), which is the older version, after 96 weeks of treatment and had lesser side-effects on patients' kidneys and bones.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins